The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes
Open accessAbstract
Ras-induced malignant transformation requires Ras farnesylation, a lipid posttranslational modification catalyzed by farnesyltransferase (FTase). Inhibitors of this enzyme have been shown to block Ras-dependent transformation, but the mechanism by which this occurs remains largely unknown. We have designed FTI-276, a peptide mimetic of the COOH-terminal Cys-Val-Ile-Met of K-Ras4B that inhibited potently FTase in vitro (IC50 = 500 pM) and was highly selective for FTase over geranylgeranyltransferase I (GGTase I) (IC50 = 50 nM). FTI-277, the methyl ester derivative of FTI-276, was extremely potent (IC50 = 100 nM) at inhibiting H-Ras, but not the geranylgeranylated Rap1A processing in whole cells. Treatment of H-Ras oncogene-transformed NIH 3T3 cells with FTI-277 blocked recruitment to the plasma membrane and subsequent activation of the serine/threonine kinase c-Raf-1 in cells transformed by farnesylated Ras (H-RasF), but not geranylgeranylated, Ras (H-RasGG). FTI-277 induced accumulation of cytoplasmic non-farnesylated H-Ras that was able to bind Raf and form cytoplasmic Ras/Raf complexes in which Raf kinase was not activated. Furthermore, FTI-277 blocked constitutive activation of mitogen-activated protein kinase (MAPK) in H-RasF, but not H-RasGG, or Raf-transformed cells. FTI-277 also inhibited oncogenic K-Ras4B processing and constitutive activation of MAPK, but the concentrations required were 100-fold higher than those needed for H-Ras inhibition. The results demonstrate that FTI-277 blocks Ras oncogenic signaling by accumulating inactive Ras/Raf complexes in the cytoplasm, hence preventing constitutive activation of the MAPK cascade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
All ras proteins are polyisoprenylated but only some are palmitoylated
Hancock, J. F., Magee, A. I., Childs, J. E., & Marshall, C. J. (1989) · Cell · doi:10.1016/0092-8674(89)90054-8 · Cited by 1,799
Hancock, J. F., Paterson, H., & Marshall, C. J. (1990) · Cell · doi:10.1016/0092-8674(90)90294-o · Cited by 1,059
Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane
Leevers, S. J., Paterson, H. F., & Marshall, C. J. (1994) · Nature · doi:10.1038/369411a0 · Cited by 1,011
MAP kinase kinase kinase, MAP kinase kinase and MAP kinase
Marshall, C. J. (1994) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(94)90095-7 · Cited by 999
Important Advances in Oncology: 1986
Merrill, J. M. (1986) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1986.03380040106043 · Cited by 907
p21ras is modified by a farnesyl isoprenoid.
Casey, P. J., Solski, P. A., Der, C. J., & Buss, J. E. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.21.8323 · Cited by 856
Self-citationInhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides
Reiss, Y., Goldstein, J. L., Seabra, M. C., Casey, P. J., & Brown, M. S. (1990) · Cell · doi:10.1016/0092-8674(90)90242-7 · Cited by 817
Important Advances in Oncology
DeVita, V. T., Hellman, S., & Rosenberg, S. A. (1991) · Anti-Cancer Drugs · doi:10.1097/00001813-199108000-00014 · Cited by 760
Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation In Animal Cells
James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., McDowell, R. S., Crowley, C. W., Lucas, B. K., Levinson, A. D., & Marsters, J. C. (1993) · Science · doi:10.1126/science.8316834 · Cited by 630
The p21 ras C-terminus is required for transformation and membrane association
Willumsen, B. M., Christensen, A., Hubbert, N. L., Papageorge, A. G., & Lowy, D. R. (1984) · Nature · doi:10.1038/310583a0 · Cited by 584
Sequence dependence of protein isoprenylation
Moores, S. L., Schaber, M. D., Mosser, S. D., Rands, E., O'Hara, M. B., Garsky, V. M., Marshall, M. S., Pompliano, D. L., & Gibbs, J. B. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98729-6 · Cited by 580
Selective Inhibition of ras -Dependent Transformation by a Farnesyltransferase Inhibitor
Kohl, N. E., Mosser, S. D., deSolms, S. J., Giuliani, E. A., Pompliano, D. L., Graham, S. L., Smith, R. L., Scolnick, E. M., Oliff, A., & Gibbs, J. B. (1993) · Science · doi:10.1126/science.8316833 · Cited by 579
Kato, K., Cox, A. D., Hisaka, M. M., Graham, S. M., Buss, J. E., & Der, C. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.14.6403 · Cited by 540
Self-citationFarnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic
Gibbs, J. B., Oliff, A., & Kohl, N. E. (1994) · Cell · doi:10.1016/0092-8674(94)90308-5 · Cited by 517
Gutierrez, L., Magee, A. I., Marshall, C. J., & Hancock, J. F. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb03478.x · Cited by 460
Ras C-terminal processing enzymes—New drug targets?
Gibbs, J. B. (1991) · Cell · doi:10.1016/0092-8674(91)90352-y · Cited by 454
McCormick, F. (1993) · Nature · doi:10.1038/363015a0 · Cited by 408
Willumsen, B. M., Norris, K., Papageorge, A. G., Hubbert, N. L., & Lowy, D. R. (1984) · The EMBO Journal · doi:10.1002/j.1460-2075.1984.tb02177.x · Cited by 399
Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation.
Jackson, J. H., Cochrane, C. G., Bourne, J. R., Solski, P. A., Buss, J. E., & Der, C. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.8.3042 · Cited by 338
Self-citationJames, G. L., Goldstein, J. L., & Brown, M. S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.11.6221 · Cited by 290
Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice.
Kohl, N. E., Wilson, F. R., Mosser, S. D., Giuliani, E., deSolms, S. J., Conner, M. W., Anthony, N. J., Holtz, W. J., Gomez, R. P., & Lee, T. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.19.9141 · Cited by 285
Definition of the human raf amino-terminal regulatory region by deletion mutagenesis.
Stanton, V. P., Nichols, D. W., Laudano, A. P., & Cooper, G. M. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.2.639 · Cited by 236
Sun, J., Qian, Y., Hamilton, A. D., & Sebti, S. M. (1995) · PubMed · Cited by 227
Self-citationActivators and effectors of ras p21 proteins
McCormick, F. (1994) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(94)90093-0 · Cited by 224
Peptidomimetic inhibitors of Ras farnesylation and function in whole cells.
Garcia, A. M., Rowell, C., Ackermann, K., Kowalczyk, J. J., & Lewis, M. D. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)46638-5 · Cited by 220
Interaction of Ras and Raf in intact mammalian cells upon extracellular stimulation.
Hallberg, B., Rayter, S. I., & Downward, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41718-2 · Cited by 218
Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein.
Cox, A. D., Hisaka, M. M., Buss, J. E., & Der, C. J. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.6.2606 · Cited by 178
Self-citationLerner, E. C., Qian, Y., Hamilton, A. D., & Sebti, S. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.26770 · Cited by 172
Self-citationReiss, Y., Seabra, M. C., Armstrong, S. A., Slaughter, C. A., Goldstein, J. L., & Brown, M. S. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99276-8 · Cited by 170
Activation of the Cellular Proto-Oncogene Product p21Ras by Addition of a Myristylation Signal
Buss, J. E., Solski, P. A., Schaeffer, J., Macdonald, M. J., & Der, C. J. (1989) · Science · doi:10.1126/science.2648572 · Cited by 156
Self-citationIdentification and preliminary characterization of protein-cysteine farnesyltransferase.
Manne, V., Roberts, D., Tobin, A., O’Rourke, E. C., Virgilio, M. D., Meyers, C. A., Ahmed, N., Kurz, B., Resh, M. D., & Kung, H. F. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.19.7541 · Cited by 144
Nigam, M., Seong, C. M., Qian, Y., Hamilton, A. D., & Sebti, S. M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36832-2 · Cited by 114
Self-citationJames, G. L., Brown, M. S., Cobb, M. H., & Goldstein, J. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47043-3 · Cited by 108
Gibbs, W. W., Schaber, M. D., Schofield, T. L., Scolnick, E. M., & Sigal, I. S. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.17.6630 · Cited by 99
Cited by
Takai, Y., Sasaki, T., & Matozaki, T. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.1.153 · Cited by 2,475
Luckman, S. P., Hughes, D. E., Coxon, F. P., Russell, R. G. G., & Dr. Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.4.581 · Cited by 1,176
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865
The complexity of Raf-1 regulation
Morrison, D. K., & Cutler, R. E. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80060-9 · Cited by 635
Targeting protein prenylation for cancer therapy
Berndt, N., Hamilton, A. D., & Sebti, S. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3151 · Cited by 614
Self-citation
Metadata
- Authors
- Lerner, E. C., Qian, Y., Blaskovich, M. A., Fossum, R. D., Vogt, A., Sun, J., Cox, A. D., Der, C. J., Hamilton, A. D., & Sebti, S. M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1995-11
- Volume
- 270
- Issue
- 45
- Pages
- 26802-26806
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2061234826
- Cited by
- 361
- References
- 35
- FWCI
- 6.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.